Source of hematopoietic progenitor cells determines their capacity to generate innate lymphoid cells ex vivo

Cytotherapy. 2024 Apr;26(4):334-339. doi: 10.1016/j.jcyt.2024.01.013. Epub 2024 Feb 15.

Abstract

Background aims: The success of allogeneic hematopoietic cell transplantation (HCT) as therapy for hematologic conditions is negatively impacted by the occurrence of graft-versus-host disease (GVHD). Tissue damage, caused, for example, by chemotherapy and radiotherapy, is a key factor in GVHD pathogenesis. Innate lymphoid cells (ILCs) are important mediators of tissue repair and homeostasis. The presence of ILCs before, and enhanced ILC reconstitution after, allogeneic HCT is associated with a reduced risk to develop mucositis and GVHD. However, ILC reconstitution after allogeneic HCT is slow and often incomplete. A way to replenish the pool of ILC relies on the differentiation of hematopoietic progenitor cells (HPCs) into ILC.

Methods: We developed an ex vivo stromal cell-containing culture system to study the capacity of HPCs to differentiate into all mature helper ILC subsets.

Results: ILC development depended on the source of HPCs. ILCs developed at high frequencies from umbilical cord blood- and fetal liver-derived HPC and at low frequencies when HPCs were obtained from allogeneic or autologous adult HCT grafts or healthy adult bone marrow. Although all helper ILC subsets could be generated from adult HPC sources, development of tissue protective ILC2 and NKp44+ ILC3 was notoriously difficult.

Conclusions: Our data suggest that slow ILC recovery after allogeneic HCT may be related to an intrinsic incapability of adult HPC to develop into ILC.

Keywords: GVHD; ILC; ILC development; allogeneic HCT; immune reconstitution.

MeSH terms

  • Adult
  • Bone Marrow
  • Graft vs Host Disease* / etiology
  • Graft vs Host Disease* / therapy
  • Hematopoietic Stem Cells
  • Humans
  • Immunity, Innate
  • Lymphocytes*